AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 281 min read$GKOS

Navratil Tomas sold $249K of GKOS

Navratil Tomas (CHIEF DEVELOPMENT OFFICER) sold 1,615 shares of GLAUKOS Corp (GKOS) at an average of $154.28 ($151.70–$154.88, $0.25M total) across 4 trades on 2026-09-25 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Navratil Tomas
Published Sep 28, 2026, 10:23 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 29, 2026, 2:50 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$GKOS
Bearish
medium confidence
Mentioned
$GKOS
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GKOSBearishLow
01

Why it matters

The filing adds a new data point about insider holdings but is unlikely to move the stock significantly.

02

Market read

A modest insider sell; limited trading relevance unless larger pattern emerges.

03

What to watch

Potential upcoming corporate actions or personal tax planning could be driving the sale, not company performance.

Relevance 3/10Novelty 3/10Timing: after‑hours filing on 2026‑09‑28

Background

Form 4 disclosures provide transparent insight into insider transactions. Small sales by executives are common and often do not precede material corporate events.

Company-level read

Ticker impact

$GKOSBearishMedium confidence
Context

Chief Development Officer Navratil Tomas sold 1,615 shares for $249K via a 10b5‑1 plan, reducing his stake to 70,818 shares.

Expected impact

likely slight pressure as the market prices in the insider sell

Evidence & confidence

Form 4 filing is a primary source; the transaction size is modest, so any price effect is expected to be limited.

Market effects

Sector

Minimal impact on the medical device sector; insider activity is routine.

Regional

None

Global

None

Counterpoint

What could challenge this read

The sale could be unrelated to fundamentals; investors may view it as routine liquidity management.

Key entities

  • Company
    Glaukos Corp

    NASDAQ‑listed ophthalmic device manufacturer.

  • Executive
    Navratil Tomas

    Chief Development Officer of Glaukos.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

GKOS insider trading history →

Related articles

OCT 9
$GKOSMed

Glaukos Strengthens Retinal Pipeline Through RevOpsis Licensing Deal

Glaukos Corporation (GKOS) licensed RO-104, a tri-specific biologic for retinal diseases, from RevOpsis Therapeutics. The deal grants GKOS exclusive rights to RevOpsis' RevMod platform for up to four additional candidates. GKOS stock fell 6.3% post-announcement but is up 42.8% year-to-date. The agreement aims to expand GKOS' retinal therapeutics pipeline and market presence.

theglobeandmail.com3 min
OCT 9
$GKOSMed

Glaukos Corp (GKOS) Reports Positive Phase 4 Trial Results for i

Glaukos Corp (GKOS) reported positive phase 4 trial results for its iDose TR implant, showing significant reduction in intraocular pressure. The company trades at a P/S ratio of 15.24, above historical and industry medians, reflecting growth expectations. It has a GF Score of 79, indicating strong growth and financial health despite unprofitability. Insiders sold $67.8M in shares over the past year, while institutional investors increased holdings.

gurufocus.com2 min
OCT 9
$GKOSMed

Glaukos Reveals Superior Intraocular Pressure Reduction With Novel Eye Therapy - Glaukos (NYSE:GKOS)

Glaukos (NYSE:GKOS) reported positive Phase 4 trial results for its iDose TR therapy combined with cataract surgery. The treatment reduced intraocular pressure by 11.1 mmHg vs. 7.4 mmHg for surgery alone, meeting primary efficacy goals. The study showed no serious safety issues. The therapy aims to improve patient compliance with long-lasting drug delivery. GKOS shares are up 0.12% at $161.49.

benzinga.com2 min
OCT 9
$GKOSMedAI 9/10

Glaukos Reports Positive Phase 4 Results for iDose TR

Glaukos Corp. reported positive Phase 4 results for its iDose TR glaucoma treatment, meeting the primary endpoint and showing superiority in reducing intraocular pressure. The company also secured an exclusive licensing agreement with RevOpsis Therapeutics for retinal disease treatments. Shares of Glaukos (GKOS) were trading at $161.16 with a $9.5 billion market cap.

ocbj.com2 min